The role of antioxidants in the long-term glycation of low density lipoprotein and its Cu²⁺-catalyzed oxidation

References

• Witztum J.L., Steinberg D. Role of oxidized LDL in atherogenesis. Journal of Clinical Investigation 1991; 88: 1785–1792
   PubMed Web of Science ®Google Scholar
• Goldstein J.L., Ho Y.K., Basu S.K., Brown M.S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proceedings of the National Academy of Sciences, USA 1979; 76: 333–337
   PubMed Web of Science ®Google Scholar
• Taniguchi N. Clinical significance of superoxide dismutase changes in aging, diabetes, ischemia, and cancer. Advances in Clinical Chemistry 1992; 29: 1–59
   PubMed Web of Science ®Google Scholar
• Mullarkey C.J., Edelstein D., Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochemical Biophysical Research Communications 1990; 173: 932–939
   PubMed Web of Science ®Google Scholar
• Schleicher E., Deufel T., Wieland O.H. Non-enzymatic glycosylation of human serum lipoproteins. FEBS Letters 1981; 129: 1–4
   PubMed Web of Science ®Google Scholar
• Festa A., Schmölzer B., Schernthaner G., Menzel E.J. Differential expression of receptors for AGEs on monocytes from patients with IDDM. Diabetologia 1998; 41: 674–680
   PubMed Web of Science ®Google Scholar
• Monnier V.M., Kohn R.R., Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proceedings of the National Academy of Sciences, USA 1984; 81: 583–587
   PubMed Web of Science ®Google Scholar
• Vlassara H., Brownlee M., Cerami A. High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proceedings of the National Academy of Sciences, USA 1985; 82: 5588–5592
   PubMed Web of Science ®Google Scholar
• Skolnik E.Y., Yang Z., Makita Z., Radoff S., Kirstein M., Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodeling and diabetic nephropathy. Journal of Experimental Medicine 1991; 174: 931–939
   PubMed Web of Science ®Google Scholar
• Dominiczak M.H. The significance of the products of the Maillard (browning) reaction in diabetes. Diabetic Medicine 1991; 8: 505–516
   PubMed Web of Science ®Google Scholar
• Sengoelge G., Födinger M., Skoupy S., Ferrara I., Zangerle C., Rogy M., Sunder-Plassmann G., Menzel E.J. Modification of fibronectin by advanced glycation upregulates endothelial cell adhesion molecules and enhances transmigration of polymorphonuclear leukocytes in response to inflammatory stimuli. Kidney International 1998; 54: 1637–1651
   PubMed Web of Science ®Google Scholar
• Dimitriadis E., Griffin M., Owens D., Johnson A., Collins P., Tomkin G.H. Oxidation of low-density lipoprotein in NIDDM: its relationship to fatty acid composition. Diabetologia 1995; 38: 1300–1306
   PubMed Web of Science ®Google Scholar
• Klein R.L., Laimins M., Lopes-Virella M.F. Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic patients. Diabetes 1995; 44: 1093–1098
   PubMed Web of Science ®Google Scholar
• Bucala R., Makita Z., Vega G., Grundy S., Koschinsky T., Cerami A., Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proceedings of the National Academy of Sciences, USA 1994; 91: 9441–9445
   PubMed Web of Science ®Google Scholar
• Esterbauer H., Gebicki J., Puhl H., Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radical Biology and Medicine 1992; 13: 341–390
   PubMed Web of Science ®Google Scholar
• Jackson R.L., Ku G., Thomas C.E. Antioxidants: a biological defense mechanism for the prevention of atherosclerosis. Medical Research Review 1993; 13: 161–182
   PubMed Web of Science ®Google Scholar
• Li D., Devaraj S., Fuller C., Bucala R., Jialal I. Effect of α-tocopherol on LDL oxidation and glycation: in vitro and in vivo studies. Journal of Lipid Research 1994; 37: 1978–1986
   Web of Science ®Google Scholar
• Ceriello A., Giugliano D., Quatraro D., Donzella C., Dipalo G., Lefebvre P.J. Vitamin E reduction of protein glycosylation in diabetes: new prospect for prevention of diabetic complications?. Diabetes Care 1991; 14: 68–72
   PubMed Web of Science ®Google Scholar
• Jialal I., Vega G., Grundy S.M. Physiologic levels of ascorbate inhibit the oxidative modification of LDL. Atherosclerosis 1990; 82: 185–191
   PubMed Web of Science ®Google Scholar
• Jialal I., Grundy S.M. Preservation of endogenous antioxidants in LDL by ascorbate but not probucol during oxidative modification. Journal of Clinical Investigation 1991; 87: 597–601
   PubMed Web of Science ®Google Scholar
• Davie S.J., Gould B.J., Yudkin J.S. Effect of vitamin C on glycosylation of proteins. Diabetes 1992; 41: 167–173
   PubMed Web of Science ®Google Scholar
• Brownlee M., Vlassara H., Kooney A., Ulrich P., Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629–1632
   PubMed Web of Science ®Google Scholar
• Reihsner R., Menzel E.J. Two-dimensional stress-relaxation behavior of human skin as influenced by non-enzymatic glycation and the inhibitory agent aminoguanidine. Journal of Biomechanics 1998; 31: 985–993
   PubMed Web of Science ®Google Scholar
• Picard S., Parthasarathy S., Fruebis J., Witztum J. Aminoguanidine inhibits oxidative modification of LDL and the subsequent increase in uptake by macrophage scavenger receptors. Proceedings of the National Academy of Sciences, USA 1992; 89: 6876–6880
   PubMed Web of Science ®Google Scholar
• Scaccini C., Chiesa G., Jialal I. A critical assessment of the effects of aminoguanidine and ascorbate on the oxidative modification of LDL: evidence for interference with some assays of lipoprotein oxidation by aminoguanidine. Journal of Lipid Research 1994; 35: 1085–1092
   PubMed Web of Science ®Google Scholar
• Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods in Enzymology 1978; 52: 302–312
   PubMedGoogle Scholar
• Bucala R., Makita Z., Koschinsky T., Cerami A., Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proceedings of the National Academy of Sciences, USA 1993; 90: 6434–6438
   PubMed Web of Science ®Google Scholar
• Kobayashi K., Watanabe J., Umeda F., Nawata H. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocrine Journal 1995; 42: 461–465
   PubMed Web of Science ®Google Scholar
• Sakurai T., Kimura S., Nakano M., Kimura H. Oxidative modification of glycated low density lipoprotein in the presence of iron. Biochemical Biophysical Research Communications 1991; 177: 433–439
   PubMed Web of Science ®Google Scholar
• Babiy A.V., Gebicki J.M., Sullivan D.R., Willey K. Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation. Biochemical Pharmacology 1992; 43: 995–1000
   PubMed Web of Science ®Google Scholar
• Bowie A., Owens D., Collins P., Johnson A., Tomkin G.H. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient?. Atherosclerosis 1993; 102: 63–67
   PubMed Web of Science ®Google Scholar
• Tsai E.C., Hirsch I.B., Brunzell J.D., Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994; 43: 1010–1014
   PubMed Web of Science ®Google Scholar
• Abuja P.M., Albertini R., Esterbauer H. Simulation of the induction of oxidation of low-density lipoprotein by high copper concentrations: evidence for a nonconstant rate of initiation. Chemical Research in Toxicology 1997; 10: 644–651
   PubMed Web of Science ®Google Scholar
• Zyzak D.V., Richardson J.M., Thorpe S.R., Baynes J.W. Formation of reactive intermediates from Amadori compounds under physiological conditions. Archives of Biochemistry and Biophysics 1995; 316: 547–554
   PubMed Web of Science ®Google Scholar
• Wolff P., Dean R.T. Glucose autoxidation and protein modification. Biochemical Journal 1987; 245: 243–250
   PubMed Web of Science ®Google Scholar
• Fu M., Wells-Knecht K.J., Blackledge J.A., Lyons T.J., Thorpe S., Baynes J.W. Glycation, glycoxidation, and cross-linking of collagen by glucose. Diabetes 1994; 43: 676–683
   PubMed Web of Science ®Google Scholar
• Pinckard R.N., Hawkins D., Farr R.S. In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature 1968; 219: 68–71
   PubMed Web of Science ®Google Scholar
• Li W., Khatami M., Robertson G.A., Shen S., Rockey J.H. Nonenzymatic glycation of bovine retinal microvessel basement membranes in vitro. Kinetic analysis and inhibition by aspirin. Investigative Ophthalmology and Visual Sciences 1984; 25: 884–892
   PubMed Web of Science ®Google Scholar
• Ziouzenkova O., Gieseg S.P., Ramos P., Esterbauer H. Factors affecting resistance of low density lipoproteins to oxidation. Lipids 1996; 31: 71–76
   PubMed Web of Science ®Google Scholar
• Jessup W., Rankin S.M., De Whalley C.V., Hoult J.R.S., Scott J., Leake O.S. Alpha-tocopherol consumption during low-density-lipoprotein oxidation. Biochemical Journal 1990; 265: 399–405
   PubMed Web of Science ®Google Scholar
• Fu S., Fu M.X., Baynes J.W., Thorpe S.R., Dean R.T. Presence of dopa and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins. Biochemical Journal 1998; 330: 233–239
   PubMed Web of Science ®Google Scholar
• Contreras I., Reiser K.M., Martinez N., Giansante E., Lopez T., Suarez N., Postalian S., Molina M., Gonzalez F., Sanchez M.R., Camejo M., Blanco M.C. Effects of aspirin or basic amino acids on collagen cross-links and complications in NIDDM. Diabetes Care 1997; 20: 832–835
   PubMed Web of Science ®Google Scholar
• Inoue I., Katayama S., Takahashi K., Negishi K., Miyazaki T., Sonoda M., Komoda T. Troglitazone has a scavenging effect on reactive oxygen species. Biochemical and Biophysical Research Communications 1997; 235: 113–116
   PubMed Web of Science ®Google Scholar
• Watanabe H. ESR studies on the antioxidant activity of troglitazone. Chemical and Pharmaceutical Bulletin 1997; 45: 1851–1855
   Web of Science ®Google Scholar
• Noguchi N., Sakai H., Kato Y., Tsuchiya J., Yamamoto Y., Niki E., Horikoshi H., Kodama T. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis 1996; 123: 227–234
   PubMed Web of Science ®Google Scholar